1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukemia after immunosuppressive treatment. Issue 1 (5th September 2016) Authors: Appel, Shmuel; Nitsan, Zeev; Gelfand, Anna; Tikhmanovich, Natalia; Dorodnicov, Elena; Reznik‐Zoref, Jenia; Milo, Ron; Lugassy, Gilles; Simonovich, Azaria Journal: Neurology and clinical neuroscience Issue: Volume 5:Issue 1(2017:Jan.) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗